EQL Pharma AB (FRA:7JK) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7JK EQL Pharma AB FRA:7JK
58 GF Score
Price €2.19
! 6 Warning Signs
View Full Analysis

What is EQL Pharma AB Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


EQL Pharma AB  (FRA:7JK) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


EQL Pharma AB Cyclically Adjusted PS Ratio Related Terms


EQL Pharma AB Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for EQL Pharma AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EQL Pharma AB Cyclically Adjusted PS Ratio Chart

EQL Pharma AB Annual Data
Trend Dec16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

EQL Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.58 9.84 8.81 6.71 2.89

FRA:7JK vs ZTS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EQL Pharma AB Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where EQL Pharma AB's Cyclically Adjusted PS Ratio falls into.


FRA:7JK
58GF Score
EQL Pharma AB FRA:7JK
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EQL Pharma AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

EQL Pharma AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, EQL Pharma AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.333/134.6100*134.6100
=0.333

Current CPI (Jun. 2026) = 134.6100.

EQL Pharma AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 0.054 100.751 0.072
201606 0.020 101.019 0.027
201609 0.013 101.138 0.017
201612 0.030 102.022 0.040
201706 0.026 102.752 0.034
201709 0.028 103.279 0.036
201712 0.030 103.793 0.039
201803 0.047 103.962 0.061
201806 0.039 104.875 0.050
201809 0.048 105.679 0.061
201812 0.038 105.912 0.048
201903 0.048 105.886 0.061
201906 0.048 106.742 0.061
201909 0.059 107.214 0.074
201912 0.069 107.766 0.086
202003 0.061 106.563 0.077
202006 0.321 107.498 0.402
202009 0.080 107.635 0.100
202012 0.099 108.296 0.123
202103 0.088 108.360 0.109
202106 0.126 108.928 0.156
202109 0.177 110.338 0.216
202112 0.399 112.486 0.477
202206 0.151 118.384 0.172
202209 0.237 122.296 0.261
202212 0.252 126.365 0.268
202303 0.164 127.042 0.174
202306 0.166 129.407 0.173
202309 0.174 130.224 0.180
202312 0.207 131.912 0.211
202403 0.232 132.205 0.236
202406 0.248 132.716 0.252
202409 0.256 132.304 0.260
202412 0.268 132.987 0.271
202503 0.337 132.825 0.342
202506 0.327 133.699 0.329
202509 0.263 133.480 0.265
202512 0.363 133.380 0.366
202603 0.381 133.550 0.384
202606 0.333 134.610 0.333

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


EQL Pharma AB Business Description

Other Exchanges EQL:Sweden7JK:Germany
Address Stortorget 1, 3rd Floor, Lund, SWE, 222 23
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
58GF Score

Get the complete analysis for FRA:7JK

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.19
Price